Drug Trial Radar · NCT06987513
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
May 15, 2025
Primary completion
Jul 30, 2026
Study completion Jul 30, 2026
Sponsor
- Lead sponsor
- Altimmune, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms: * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Conditions
- Alcohol Use Disorder (AUD)
Interventions
PemvidutideDrug
Pemvidutide 2.4 mg SC once weekly
PlaceboOther
Placebo SC once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the average number of heavy drinking days per weekTime frame: Baseline to Weeks 21-24
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Altimmune Clinical Study Site
Los Angeles, California
Altimmune Clinical Study Site
Aurora, Colorado
Altimmune Clinical Study Site
New Haven, Connecticut
Altimmune Clinical Study Site
Fort Myers, Florida
Altimmune Clinical Study Site
University Park, Florida
Altimmune Clinical Study Site
North Canton, Ohio
Altimmune Clinical Study Site
Tulsa, Oklahoma
Altimmune Clinical Study Site
Philadelphia, Pennsylvania
Altimmune Clinical Study Site
Providence, Rhode Island
Altimmune Clinical Study Site
Charleston, South Carolina
Altimmune Clinical Study Site
Charlottesville, Virginia
Altimmune Clinical Study Site
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.